GSK (LON:GSK) Earns "Hold" Rating from Deutsche Bank Aktiengesellschaft

GSK (LON:GSK - Get Free Report)'s stock had its "hold" rating restated by investment analysts at Deutsche Bank Aktiengesellschaft in a research report issued to clients and investors on Monday, Marketbeat.com reports. They presently have a GBX 1,450 ($19.45) price target on the stock. Deutsche Bank Aktiengesellschaft's target price suggests a potential upside of 7.58% from the stock's previous close.

Several other brokerages also recently weighed in on GSK. Shore Capital restated a "buy" rating and issued a GBX 2,000 ($26.83) target price on shares of GSK in a research note on Friday. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research note on Friday. Finally, Berenberg Bank reiterated a "hold" rating and set a GBX 1,600 ($21.46) price objective on shares of GSK in a research note on Friday.

GSK Stock Performance

Shares of LON:GSK opened at GBX 1,347.84 ($18.08) on Monday. The firm has a market cap of £54.69 billion, a PE ratio of 21.77, a price-to-earnings-growth ratio of 1.24 and a beta of 0.31. The firm's 50 day simple moving average is GBX 1,435.32 and its 200-day simple moving average is GBX 1,423.08. GSK has a one year low of GBX 1,242.50 ($16.67) and a one year high of GBX 1,678.68 ($22.52). The company has a debt-to-equity ratio of 114.64, a quick ratio of 0.73 and a current ratio of 0.81.

GSK (LON:GSK - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported GBX 44.90 ($0.60) EPS for the quarter. GSK had a net margin of 8.02% and a return on equity of 18.08%. As a group, equities analysts predict that GSK will post 175.980975 EPS for the current year.

Insider Buying and Selling at GSK

In other GSK news, insider Wendy Becker bought 545 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were purchased at an average cost of GBX 1,435 ($19.25) per share, with a total value of £7,820.75 ($10,490.61). Also, insider Jonathan Symonds bought 1,350 shares of the business's stock in a transaction that occurred on Friday, June 20th. The shares were acquired at an average cost of GBX 1,435 ($19.25) per share, for a total transaction of £19,372.50 ($25,985.92). Insiders have bought 1,905 shares of company stock worth $2,732,835 in the last ninety days. 1.61% of the stock is owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.